TY - JOUR
T1 - Suppression of rat retinal ganglion cell death by PACAP following transient ischemia induced by high intraocular pressure
AU - Seki, Tamotsu
AU - Itoh, Hiroyuki
AU - Nakamachi, Tomoya
AU - Endo, Kimi
AU - Wada, Yoshihiro
AU - Nakamura, Keisuke
AU - Shioda, Seiji
N1 - Funding Information:
Acknowledgement This study was supported by Ministry of Education, Science, Sports, and Culture of Japan and in part by a High-Technology Research Center Project from the Ministry of Education, Science, Sports, and Culture of Japan.
PY - 2011/1
Y1 - 2011/1
N2 - Glaucoma is a neurodegenerative disease in which increasing intraocular pressure leads to the progressive loss of retinal ganglion cells (RGCs) and blindness. Here, we report a neuroprotective effect of pituitary adenylate cyclase-activating polypeptide (PACAP) against RGC loss induced by high intraocular pressure in the rat. Vehicle or PACAP (1 fM to 1,000 pM) solution was injected into the vitreous body once after induction of a high intraocular pressure (110 mmHg). Seven days later, the number of viable RGCs was reduced to 45% of that in the intact control. However, PACAP treatment significantly reduced this RGC death in a bimodal manner, with peaks at 10 fM and 10-100 pM. The cAMP antagonist Rp-cAMP significantly blocked the neuroprotective effect of PACAP at both high and low doses, whereas the MAP kinase inhibitor PD-98059 only prevented the effect of the low dose of PACAP. These findings suggest that PACAP has bimodal effects in the neuroprotection of RGCs against ischemia and that these effects are mediated via different signaling pathways.
AB - Glaucoma is a neurodegenerative disease in which increasing intraocular pressure leads to the progressive loss of retinal ganglion cells (RGCs) and blindness. Here, we report a neuroprotective effect of pituitary adenylate cyclase-activating polypeptide (PACAP) against RGC loss induced by high intraocular pressure in the rat. Vehicle or PACAP (1 fM to 1,000 pM) solution was injected into the vitreous body once after induction of a high intraocular pressure (110 mmHg). Seven days later, the number of viable RGCs was reduced to 45% of that in the intact control. However, PACAP treatment significantly reduced this RGC death in a bimodal manner, with peaks at 10 fM and 10-100 pM. The cAMP antagonist Rp-cAMP significantly blocked the neuroprotective effect of PACAP at both high and low doses, whereas the MAP kinase inhibitor PD-98059 only prevented the effect of the low dose of PACAP. These findings suggest that PACAP has bimodal effects in the neuroprotection of RGCs against ischemia and that these effects are mediated via different signaling pathways.
KW - Ganglion cell
KW - Glaucoma
KW - Intraocular hypertension
KW - Pituitary adenylate cyclase-activating polypeptide (PACAP)
KW - Retina
UR - http://www.scopus.com/inward/record.url?scp=79951576698&partnerID=8YFLogxK
U2 - 10.1007/s12031-010-9410-5
DO - 10.1007/s12031-010-9410-5
M3 - 学術論文
C2 - 20585899
AN - SCOPUS:79951576698
SN - 0895-8696
VL - 43
SP - 30
EP - 34
JO - Journal of Molecular Neuroscience
JF - Journal of Molecular Neuroscience
IS - 1
ER -